Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹371.70
3.95 (1.07%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹3.39K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
17.2
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹318.95+16.5%
52W High₹564.05-34.1%
Current Price
₹371.70
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹297.36
Upper Circuit₹446.04
Reference Price
₹371.70
Investment Checklist
Triple Top on 1W (BREAKOUT CONFIRMED) — target ₹406.25
Double Top on 1W (BREAKOUT CONFIRMED) — target ₹406.25
Composite score -40.96 (SELL) with 81.1% confidence
Trend: Price below most MAs — downtrend
10/20 Bearish Cross detected 3 day(s) ago
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
81%
Trend
BEARISH
BEARISH
Price below most MAs — downtrend
EMA20
376.33
EMA50
373.93
EMA200
409.19
Price Action
MIXED
NEUTRAL
Higher Highs3
Higher Lows4
Lower Highs6
Lower Lows5
Support & Resistance Levels
Resistance (Above)
₹376.50
₹402.45
₹407.20
₹423.75
₹431.00
Support (Below)
₹364.42
₹356.20
₹343.85
₹325.60
₹318.95
Volume Analysis
TrendDECREASING
Change-46.50%
Unusual VolumeNo
Recent MA Crossovers
10/20 Bearish Cross
3 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹367.98
3% Risk₹360.55
5% Risk₹353.11
7% Risk (Custom)
₹345.68Technical Levels
1x ATR (Volatility)₹359.78
2x ATR (Swing)₹347.86
3x ATR (Trend)₹335.94
Immediate Support₹364.42
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹658.7 Cr | ₹590.5 Cr | ₹652.8 Cr | ₹601.7 Cr |
| Net Profit | ₹62.9 Cr | ₹53.9 Cr | ₹45.3 Cr | ₹40.5 Cr |
| EPS | — | ₹5.91 | ₹4.95 | ₹4.44 |
| Operating Profit | ₹95.2 Cr | ₹74.4 Cr | ₹84.4 Cr | ₹56.3 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 09 Feb 2026 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
| 04 Feb 2025 | Interim Dividend - Re 1 Per Share | INTERIM_DIVIDEND |
| 05 Sept 2024 | Buy Back | BUYBACK |
| 06 Feb 2024 | Interim Dividend - Re 1 Per Share | INTERIM_DIVIDEND |
| 04 Aug 2023 | Buy Back | BUYBACK |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for AARTIDRUGS
View All
neutral
CNBC TV18 - Markets 26d ago
Eight Pharma stocks that should be on your radar on Monday
Pharmaceutical companies reported a slew of updates over the weekend. Earnings reactions from KIMS, Global Health, Gland Pharma, Aarti Drugs, to a USFDA observation list for Emcure Pharma, these are the drugmakers that should be on your radar today.
AARTIDRUGSAARTIINDEMCUREGLANDGLOBALKIMSMEDANTAChemicalsConsumer Services
NEWS
positive
Business Standard - Markets 28d ago
Aarti Drugs consolidated net profit declines 12.20% in the March 2026 quarter
Sales rise 6.43% to Rs 720.30 crore
AARTIDRUGSAARTIINDChemicalsHealthcare
positive
CNBC TV18 - Markets 28d ago
Aarti Drugs Q4 profit falls 12% despite revenue growth
Revenue rises 6.4% year-on-year; EBITDA margin remains largely stable
AARTIDRUGSAARTIINDMOGSECChemicalsFinancial Services